SCHEMBL14979874

SCHEMBL14979874

C=CCc1c(O[C@H]2CN[C@H](C(=O)OC)C2)nc2ccccc2c1OCC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK2 O96017 2/20 0.40
PIM1 P11309 1/20 0.36
P2RX3 P56373 1/20 0.34
KDR P35968 2/20 0.34
F2 P00734 1/20 0.33
F10 P00742 1/20 0.33
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 4/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
HTR3E A5X5Y0 1/20 0.32
HTR3B O95264 1/20 0.32
HTR3A P46098 1/20 0.32
HTR3D Q70Z44 1/20 0.32
HTR3C Q8WXA8 1/20 0.32
GAA P10253 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2D6 P10635 1/20 0.32
MAPT P10636 1/20 0.32
CYP2C9 P11712 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17704164 0.92 HTR3E (0.33) F2F10ALDH1A1KDM4ENPC1
SCHEMBL15096209 0.92 CHEK2 (0.39) CHEK2PIM1P2RX3KDRALDH1A1
SCHEMBL15093389 0.82 GRIK1 (0.35) MAPT
SCHEMBL14979944 0.78 P2RX3 (0.40) P2RX3
SCHEMBL21508756 0.78 P2RY12 (0.36) ALDH1A1
SCHEMBL16106959 0.77 HTR3E (0.36) ALDH1A1KDM4ERAB9AHTR3EHTR3B
SCHEMBL14969332 0.77 HTR3E (0.34) ALDH1A1KDM4ENPC1RAB9AHTR3E
SCHEMBL21508741 0.76 HTR3E (0.32) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL16077806 0.75 PIM1 (0.39) CHEK2PIM1P2RX3KDRALDH1A1
SCHEMBL1072609 0.74 CHEK2 (0.42) CHEK2PIM1P2RX3KDRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2780026-B1 HCV NS3 PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2019-10-23 EP disclosed
US-9328138-B2 HCV NS3 protease inhibitors MSD ITALIA S.R.L. (IT) 2016-05-03 US disclosed
US-9328138-B2 HCV NS3 protease inhibitors MSD ITALIA S.R.L. (IT) 2016-05-03 US disclosed
US-20140296136-A1 HCV NS3 PROTEASE INHIBITORS MERCK SHARP & DOHME LLC 2014-10-02 US disclosed
US-20140296136-A1 HCV NS3 PROTEASE INHIBITORS MERCK SHARP & DOHME LLC 2014-10-02 US disclosed
US-20140296136-A1 HCV NS3 PROTEASE INHIBITORS MERCK SHARP & DOHME LLC 2014-10-02 US disclosed
WO-2013074386-A2 HCV NS3 PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296136-A1 HCV NS3 PROTEASE INHIBITORS HAVCR2, GTF3C3, CTSC CHEK2 4360/4885PIM1 2404/4885P2RX3 3516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.